http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
시험자와 의뢰자의 임상연구코디네이터의 근무환경과 활용방안에 대한 인식
정인숙,최상민,윤지향,윤은화,Jeong, Ihn-Sook,Choe, Sang-Min,Yoon, Ji-Hyang,Yun, Eun-Hwa 대한임상약리학회 2012 臨床藥理學會誌 Vol.20 No.1
Background: This study was aimed to investigate the perception on working conditions and utilization of clinical research coordinators (CRCs) among investigators and sponsors. Methods: The participants of this cross-section study were 114 investigators and 138 sponsors including clinical research associates (CRAs) who have worked with CRCs. Data was collected with paper or electronic form of self-administered questionnaires and analyzed with descriptive statistics and ${\chi}^2$ test or t test. Results: Among investigators and sponsors, 56.1% and 95.0% perceived regular full-time positions as proper type of CRC employment, respectively. Those who perceived monthly salary with incentive as proper payment system were 67.5% of investigators and 68.8% of sponsors. The proper salary for 2-year CRCs and 5-year CRCs were significantly higher in sponsors than investigators. Investigators perceived CRCs could handle 3 studies as the same time and 5 studies per year. In regard to the difficulty in utilizing CRCs, 68.4% of investigators perceived lack of experienced CRCs and 84.8% of sponsors did frequent turnover. Those who responded pooling CRCs by hospital or clinical trial centers as a good solution to hire CRCs easily were 81.6% of investigators and 58.0% of sponsors. Conclusion: Almost all investigators and sponsors perceived CRCs were helpful for improving the quality of clinical trials. We recommend each institution or clinical trial centers could introduce the central CRCs' employment and management with proper salary and workload based on the results to maintain experienced CRCs and lessen the turnover of CRCs.
진행성 비소세포 폐암 환자에서 Gemcitabine, Cisplatin 3주 주기 복합화학요법
김석현 ( Kim Seog Hyeon ),이경원 ( Lee Gyeong Won ),윤지향 ( Yun Ji Hyang ),심기식 ( Sim Gi Sig ),이영미 ( Lee Yeong Mi ),강도연 ( Kang Do Yeon ),박정랑 ( Park Jeong Lang ),정정화 ( Jeong Jeong Hwa ),신민기 ( Sin Min Gi ),정이영 ( 대한내과학회 2004 대한내과학회지 Vol.66 No.1
진행성 비소세포 폐암 환자에서 gemcitabine 1,200 ㎎/㎡을 1일째, 8일째 투여하고, cisplatin 80 ㎎/㎡을 1일째 투여하는 3주 간격의 복합 항암 화학요법은 효과적이고, 독성 또한 감내할만 하였다. 향후 국내에서 보다 많은 수의 환자들을 대상으로 3주 간격과 4주 간격의 비교 및 용량 강도에 따른 반응률 및 생존기간이 비교 가능한 대규모의 전향적 무작위 다기관 임상 3상 연구가 이루어져야 하겠다. Background : The combination chemotherapy of gemcitabine and cisplatin has been proven effective in the treatment of advanced non-small cell lung cancer (NSCLC). However, the optimal schedule for administration of the two drugs has not yet been determined